Scientists at St. Jude Children’s Research Hospital report the creation of a database that identifies gene-regulatory mechanisms in immune cells that facilitate Type 1 diabetes. The findings “Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes” appear in Nature Immunology.
“The pool of beta cell-specific CD8+ T cells in type 1 diabetes (T1D) sustains an autoreactive potential despite having access to a constant source of antigen. To investigate the long-lived nature of these cells, we established a DNA methylation-based T cell ‘multipotency index’ and found that beta cell-specific CD8+ T cells retained a stem-like epigenetic multipotency score. Single-cell assay for transposase-accessible chromatin using sequencing confirmed the coexistence of naive and effector-associated epigenetic programs in individual beta cell-specific CD8+ T cells,” write the investigators.
“Assessment of beta cell-specific CD8+ T cell anatomical distribution and the establishment of stem-associated epigenetic programs revealed that self-reactive CD8+ T cells isolated from murine lymphoid tissue retained developmentally plastic phenotypic and epigenetic profiles relative to the same cells isolated from the pancreas. Collectively, these data provide new insight into the longevity of beta cell-specific CD8+ T cell responses and document the use of this methylation-based multipotency index for investigating human and mouse CD8+ T cell differentiation.”
In Type 1 diabetes, CD8 T cells kill insulin-producing islet cells in the pancreas. By creating an epigenetic “atlas,” the researchers revealed that these T cells have a dual biological personality which enables the T cells to retain the ability to attack insulin-producing cells across successive generations of T cells.
“A major question has been why these T cells remain functional over long periods of time,” said senior author Ben Youngblood, PhD, of the St. Jude department of immunology. “Our research provides important insights into the stability of that response by establishing the central role of epigenetic programming in human T cell differentiation.”
Youngblood and his team charted the pattern of methylation across the genome of CD8 T cells to understand the epigenetic programming that governs their development, or differentiation, from immature cells called stem-memory T cells. The researchers collected data on methylation patterns of a variety of T cells, ranging from naïve to active effector cells.
From the atlas, investigators discovered that the diabetes-causing T cells possessed a dual personality of both naïve and effector-associated epigenetic programs, revealing for the first time that the cells were epigenetic hybrids, possessing both programs. he researchers also performed the same analysis on mouse CD8 T cells, revealing they also showed such a dual personality.
A key to understanding both the human and mouse atlas was a multipotency index developed by co-authors Yiping Fan, PhD, of the St. Jude Center for Applied Bioinformatics, and Caitlin Zebley, MD, a clinical fellow in the department of Immunology. Through cutting-edge, machine-learning approaches, Fan and Zebley interrogated this data to understand the differentiation status of the autoreactive T cells. Using this novel index, they were able show that methylation sites across the T cells’ genome can be used to predict a T cell’s differentiation.
The autoreactive CD8 T cells scored high on the index, revealing their preservation of the less-differentiated hybrid state. The atlas and the multipotency index offer important new tools for developing treatments and diagnosis of Type 1 diabetes.
“We now have an epigenetic signature for these cells that we can use to explore treatments for Type 1 diabetes that induce immunological tolerance of these T cells to prevent their attack on islet cells,” Youngblood said.
The index could be used as the basis for a diagnostic tool to predict which patients would respond to therapies that encourage that tolerance. To advance this work, Youngblood and his colleagues are collaborating with the Immune Tolerance Network to examine data from past clinical trials to see whether the index could predict which patients would respond to such therapies and which would not. The ITN, funded by the National Institute of Allergy and Infectious Diseases, is a collaboration of researchers aimed at developing immune tolerance therapies.
The insights from the epigenetic atlas can also be applied to cancer immunotherapies, in which T cells are engineered to recognize and selectively attack tumor cells. Using the multipotency index, researchers could measure how effective such engineered T cells would be in attacking cancer cells. The atlas can also be used to understand the nature of T cell activity in chronic viral infections.